Fred Alger Management Inc. trimmed its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 75.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 148,697 shares of the biopharmaceutical company’s stock after selling 465,964 shares during the period. Fred Alger Management Inc. owned about 0.07% of Alexion Pharmaceuticals worth $18,092,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Guardian Life Insurance Co. of America boosted its holdings in Alexion Pharmaceuticals by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. Eqis Capital Management Inc. boosted its holdings in Alexion Pharmaceuticals by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 38 shares in the last quarter. Rathbone Brothers plc boosted its holdings in Alexion Pharmaceuticals by 2.5% during the second quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 50 shares in the last quarter. Cleararc Capital Inc. boosted its holdings in Alexion Pharmaceuticals by 1.0% during the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 53 shares in the last quarter. Finally, Seven Bridges Advisors LLC boosted its holdings in Alexion Pharmaceuticals by 2.1% during the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 94.25% of the company’s stock.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the sale, the executive vice president now directly owns 26,092 shares in the company, valued at $3,794,820.48. The disclosure for this sale can be found here. In the last three months, insiders sold 17,190 shares of company stock worth $2,433,669. 4.35% of the stock is currently owned by insiders.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 0.23% on Thursday, hitting $142.25. 203,677 shares of the stock were exchanged. The stock has a market capitalization of $31.75 billion, a P/E ratio of 61.69 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The company has a 50 day moving average of $140.86 and a 200 day moving average of $126.01.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.13 earnings per share. On average, equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.

ALXN has been the subject of a number of research reports. Cowen and Company restated an “outperform” rating and set a $122.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, July 3rd. SunTrust Banks, Inc. restated a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Morgan Stanley restated an “overweight” rating and set a $153.00 target price (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Leerink Swann raised their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Finally, Credit Suisse Group set a $164.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, June 14th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $154.56.

ILLEGAL ACTIVITY WARNING: “Fred Alger Management Inc. Trims Position in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/fred-alger-management-inc-trims-position-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.